ATLAS-seq T Cell Screening via Aptamer Cytokine Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying T Cell Receptor (TCR) candidates for TCR therapy are limited as they focus on high-affinity interactions rather than T-cell activation efficacy, which is crucial for clinical applications.
Innovation Solution
A method involving aptamer-based T Lymphocyte Activity Screening and Sequencing (ATLAS-seq) that uses cytokine-specific detectable aptamer beacons to monitor cytokine secretion from T cells upon antigen stimulation, followed by single-cell sequencing to identify activated TCRs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If MHC multimer technologies are used to isolate antigen-specific T cell populations, then high-affinity physical interactions between TCR and MHC-antigen complex are focused, but T-cell activation efficacy is not equivalent to T-cell affinity
Solution Approach 1:
The patent introduces an aptamer beacon as an intermediary molecule that detects cytokine secretion as a mediator of T-cell activation. Instead of directly measuring TCR-pMHC binding affinity, the aptamer beacon monitors the downstream effect (cytokine secretion) that indicates true T-cell activation efficacy, thereby resolving the disconnect between affinity measurement and activation efficacy
Solution Approach 2:
The patent replaces the mechanical/physical binding assay (MHC multimer binding) with a biochemical readout system (aptamer-based fluorescent detection of cytokine secretion). This substitution allows measurement of functional activation rather than just physical interaction, addressing the limitation that high affinity does not equate to high activation efficacy
2Measurement precision
If fixed cells are used to measure intracellular cytokine products, then cytokine production capacity can be measured, but actual secretion of cytokines from living cells is not measured
Solution Approach 1:
The patent employs living T cells that autonomously secrete cytokines in response to antigen stimulation within droplets. The cells serve themselves by naturally performing the secretion function without requiring fixation or lysis, allowing direct measurement of actual cytokine secretion from living cells rather than intracellular accumulation
Solution Approach 2:
The patent changes the measurement parameter from intracellular cytokine accumulation (measured in fixed cells) to extracellular cytokine secretion (measured in living cells). The aptamer beacon detects cytokines in the supernatant, reflecting the dynamic secretion process that occurs in living, functional T cells
3Productivity
If conventional bulk activation assays are used, then T cell activation can be measured, but intercellular communications and signals from other T cells or PBMCs can alter the behavior of specific T cells
Solution Approach 1:
The patent segments the bulk T cell population into individual single cells, each encapsulated in its own microdroplet. This segmentation isolates each T cell from intercellular communications and signals from other T cells or PBMCs, allowing precise measurement of specific T cell behavior without interference from neighboring cells
Solution Approach 2:
The patent uses a droplet (microfluidic compartment) as a flexible boundary that provides physical isolation for each T cell. The droplet acts as a containment shell that prevents cross-talk between cells while maintaining a controlled microenvironment for individual T cell activation and cytokine secretion measurement
4Measurement precision
If droplet-based T cell screening technology is used, then an enclosed environment for accurate measurement of each individual T cell activation can be provided, but device complexity increases
Solution Approach 1:
The patent employs a universal droplet-based platform that can measure multiple parameters (cytokine secretion, TCR activation) across different T cell samples and antigen specificities. The same microfluidic system and aptamer beacon approach can be applied to various T cell types and antigens, making the increased device complexity worthwhile through its broad applicability and high-precision measurement capabilities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach efficiently identifies TCRs based on their ability to activate T cells, providing a high-throughput method for selecting promising TCRs for immunotherapies by accurately measuring cytokine secretion in a controlled environment.
Implementation Method 1
a cytokine-specific detectable aptamer beacon that specifically binds to a cytokine
Implementation Method 2
sorted by fluorescence activated cell sorting based on activation and detection of said cytokine-specific detectable label
Data Source
AI summary
The present disclosure is directed to the accurate and high throughput method for screening and identifying antigen-reactive T Cell Receptors (TCRs) capable of triggering effective T-cell activation.